JERINI

Jerini AG to Wind Down its Preclinical Programs

Ad-hoc Announcement pursuant to § 15 German Securities Trading Act (WpHG) - mandatory information for Europe-wide distribution


Berlin, June 26, 2009 – Jerini AG has decided to end all negotiations regarding the transfer of assets associated with Jerini AG's preclinical programs and to terminate the employees associated with these programs.  The decision was taken following unsuccessful efforts to find an investor for the sale of the preclinical programs. The redundancies reduce Jerini AG's head-count by more than 45. 

ISIN: DE0006787476
WKN: 678 747
Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany
Registered Office: Berlin, Germany

For questions, please contact:
Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T  + 49 - 30 - 97893 - 285
X  + 49 - 30 - 97893 - 105
wiedenmann@jerini.com